Company Filing History:
6 out of 15 
3 out of 33 
1 out of 10 Years Active: 2010-2025
Title: Yumin Cui: Innovator in Cancer Treatment
Introduction
Yumin Cui is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of cancer treatment. With a total of 11 patents to his name, he has made remarkable advancements in the development of bispecific antigen binding proteins and multispecific Fab fusion proteins.
Latest Patents
Among his latest patents, Yumin Cui has developed anti-CD19 and anti-CD3 bispecific antigen binding proteins. This invention provides bispecific antigen binding proteins (BSAPs) that specifically bind to CD3 and a tumor antigen, such as CD19. The applications of these BSAPs include the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the BSAPs. Another notable patent is for multispecific Fab fusion proteins (MSFP) that specifically bind to CD3 and EpCAM. This invention also outlines the uses of MSFPs for pharmaceutical compositions, cancer treatment methods, and related kits.
Career Highlights
Yumin Cui has worked with notable companies in the pharmaceutical sector, including Hutchison Medipharma Enterprises Limited and Hutchison Medipharma Limited. His work has significantly impacted the development of innovative cancer therapies.
Collaborations
Yumin Cui has collaborated with esteemed colleagues such as Wei-Guo Su and Weihan Zhang, contributing to the advancement of cancer treatment technologies.
Conclusion
Yumin Cui's innovative work in the field of cancer treatment through bispecific and multispecific proteins showcases his dedication to improving therapeutic options for patients. His contributions continue to influence the landscape of cancer research and treatment.